I had the honor of interviewing Dr. Filippo Milano, Associate Director of Cord Blood Transplantation at the Fred Hutchinson Cancer Research Centre about cord blood transplantation. In this interview, Dr. Milano speaks about trends in cord blood transplantation (CBT) that are affecting the global cord blood industry. [Read more…]
BioInformant's Founder, Cade Hildreth, has interviewed hundreds of key opinion leaders (KOL's) from across the stem cell industry.
Growing Stem Cells in Suspension Bioreactors with Dr. Angel of Accellta
Dr. Itzchak Angel, CEO of the Israeli stem cell company, Accellta, has more than 30 years of experience guiding the business development efforts of new and established companies across the Israeli pharmaceutical industry. Dr. Angel was formerly Vice President of R&D at Proteologics Ltd. and at D-Pharm Biopharmaceuticals. Before those positions, he served as the head of pharmacology in Synthelabo (now Sanofi) where he launched blockbuster drugs such as Xatral, Ambien and Mizollen into the marketplace. [Read more…]
RegMed’s First Xeno-Free Human Mesenchymal Stem Cell (MSC) Cell Banks
RoosterBio has announced the launch of the Regenerative Medicine (RM) industry’s first xeno-free (XF) hMSC cell banks to advance and simplify stem cell biomanufacturing. By incorporating XF starting materials at early stages, RM scientists can perform more clinically relevant work, resulting in an expedited path towards clinical testing programs. Due of the importance of this announcement, I followed up with Dr. Priya Baraniak, Director of BD & Strategic Marketing at RoosterBio, to further explore details of the launch. [Read more…]
Use of Placental Tissue Matrix for Regenerative Medicine Applications
I am honored to release this interview with Bobby Ardila, V.P. of International Medical Communications for Neo Matrix, LLC. Neo Matrix is a newly formed cell therapy company serving the U.S.A. and South American markets.  In this interview, we explore the company’s use of a placental tissue matrix component for regenerative medicine applications.
Reversing Type I Diabetes with Encapsulated Cell Therapy Technology
This is an interview with Gary Harlem, CEO of Altucell, a company exploring novel cell therapy approaches to treating Type I diabetes. In addition to diabetes, the company’s core encapsulation technology is applicable to a wide range of autoimmune and chronic degenerative disorders.
While Altucell is an American company, it has secured intellectual property rights on encapsulation patents from a team of researchers at the University of Perugia, Italy, led by Dr. Riccardo Calafiore, M.D. [Read more…]